Morgan Stanley analyst Craig Hettenbach has maintained their neutral stance on HIMS stock, giving a Hold rating on July 9.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Craig Hettenbach has given his Hold rating due to a combination of factors that indicate a potential slowdown in Hims & Hers Health’s business momentum. The company’s app downloads have experienced their first year-over-year decline in June, marking an 8% drop compared to the previous year. This decline in app downloads is accompanied by a 5% year-over-year growth in web traffic, which is the slowest growth since March 2024.
Despite the strong stock performance year-to-date, the reversal in these key metrics suggests a potential misalignment with the company’s current market valuation. The app downloads have also decreased by 17% sequentially quarter-over-quarter, and the monthly downloads have fallen below levels seen before the launch of compounded GLP-1 in May 2024. Additionally, while the proportion of Hers downloads has increased, the overall unique web traffic growth remains modest. These factors collectively contribute to a cautious outlook, justifying the Hold rating.
According to TipRanks, Hettenbach is ranked #2687 out of 9820 analysts.
In another report released on July 9, Leerink Partners also reiterated a Hold rating on the stock with a $42.00 price target.